Minocycline, a second generation broad‐spectrum antibiotic, has been frequently postulated
to be a “microglia inhibitor.” A considerable number of publications have used minocycline …

The lack of robust treatment options available for neurodegenerative diseases, stroke, and
central nervous system (CNS) trauma, all of which often involve both inflammation and …

Minocycline is a broad-spectrum tetracycline antibiotic. A number of preclinical studies have
shown that minocycline exhibits neuroprotective effects in various animal models of …

Background and purpose Minocycline is a broad‐spectrum antibiotic, effective as a chronic
treatment for recurrent bacterial infections. Beyond its antibiotic action, minocycline also has …

Minocycline, an antibiotic of the tetracycline family, has been shown to display
neurorestorative or neuroprotective properties in various models of neurodegenerative …

Initial studies conducted on the neuroprotective effects of minocycline, a second-generation
tetracycline, in experimental models of neurodegeneration gave promising results. However …

Minocycline is a member of the tetracycline class of molecules with broad-spectrum
antibiotic activity. The unique properties of minocycline result in increased tissue distribution …

Minocycline is a semisynthetic second-generation tetracycline derivative, and many
publications provide evidence of its successful neuroprotection in a variety of animal …

Activated microglia are implicated in the pathogenesis of disease‐, trauma‐and toxicant‐
induced damage to the CNS, and strategies to modulate microglial activation are gaining …

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
cardinal features of tremor, bradykinesia, rigidity and postural instability. In addition to the …